Ask AI
Sequencing RR CLL

CME

Interactive Case Challenge: Treating R/R CLL After Progression on Frontline Acalabrutinib Plus Venetoclax and Impaired Renal Function

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 31, 2026

Expiration: January 30, 2027

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 67-year-old man with CLL experiences progressive disease while receiving first-line continuous zanubrutinib monotherapy. BTK mutation analysis shows C481S mutation. Because of his work schedule, the patient expresses preference for limiting regular clinic visits for further treatment.

Which of these treatment options is best suited for this patient in the second line?

2.

Based on recent clinical trial data and guideline updates, which of the following would be the most accurate to tell a patient about the current FDA-approved indication of pirtobrutinib in CLL/SLL?